论文部分内容阅读
目的探讨缬沙坦胶囊联合赖诺普利胶囊治疗原发性高血压的临床疗效。方法选取2016年3月—2017年2月如皋市中医院收治的原发性高血压患者142例为研究对象,采取随机分组法将所有患者分为对照组和治疗组,每组各71例。对照组晨起空腹口服赖诺普利胶囊,10 mg/次,1次/d。治疗组在对照组的基础上晨起口服缬沙坦胶囊,80 mg/次,1次/d。两组患者均连续治疗8周。观察两组的临床疗效,比较两组的血压情况。结果治疗后,对照组和治疗组总有效率分别为87.32%、97.18%,两组比较差异具有统计学意义(P<0.05)。治疗4、6、8周后,两组收缩压(SBP)和舒张压(DBP)均显著降低,同组治疗前后比较差异有统计学意义(P<0.05);且治疗组这些观察指标明显低于对照组,两组比较差异具有统计学意义(P<0.05)。结论缬沙坦胶囊联合赖诺普利胶囊治疗原发性高血压具有较好的疗效,能显著降低SBP和DBP,安全性较好,具有一定的临床推广应用价值。
Objective To investigate the clinical efficacy of valsartan capsule combined with lisinopril capsule in the treatment of essential hypertension. Methods From March 2016 to February 2017, 142 patients with essential hypertension admitted to Rugao Hospital of Traditional Chinese Medicine were selected as research objects. All patients were divided into control group and treatment group with 71 cases in each group randomly. Control group morning fasting oral lisinopril capsules, 10 mg / time, 1 / d. The treatment group on the basis of the control group, morning oral valsartan capsules, 80 mg / time, 1 / d. Two groups of patients were treated for 8 weeks. The clinical efficacy of the two groups were observed and the blood pressure was compared between the two groups. Results After treatment, the total effective rate of the control group and the treatment group was 87.32% and 97.18%, respectively, with significant difference between the two groups (P <0.05). The systolic blood pressure (SBP) and diastolic blood pressure (DBP) of the two groups were significantly decreased after 4, 6 and 8 weeks of treatment, with significant difference before and after treatment (P <0.05) In the control group, the difference between the two groups was statistically significant (P <0.05). Conclusion Valsartan capsules combined with lisinopril capsules have a good curative effect in treating essential hypertension and can significantly reduce SBP and DBP, which is safe and has some clinical application value.